Wessex Haematology NETWORK

INDOLENT LYMPHOMA

Front-line treatment of follicular lymphoma

New diagnosis follicular lymphoma

Baseline PET-CT

* Consider eligibility for clinical trials

* Consider palliative RT for patients with symptomatic disease who are unsuitable for systemic therapy

Early stage

- Stage 1: PET-CT (consider staging marrow biopsy if cytopenias or other indication of marrow involvement)
- Stage 2: if encompassable in one RT field

Refer for IFRT

Advanced stage

Stage 2 (not included above) to stage 4

Symptomatic

Meets GELF criteria

FLIPI ≥ 2

O-CHOP
O-CVP
O-Bendamustine**
Shared decision making

FLIPI < 2

R-CHOP
R-CVP
R-Bendamustine
Shared decision making

Asymptomatic

Does not meet GELF criteria

Active monitoring

End of induction PET-CT

Consider obinutuzumab/rituximab maintenance

*** Evaluate benefit in the setting of COVID-19 risk and PET response, and employ shared decision making*

GELF criteria

- Any nodal or extranodal mass ≥ 7 cm
- 3 nodal sites, each > 3 cm
- B symptoms; splenomegaly
- Compression/compromise of vital organs
- Pleural or peritoneal serous effusion
- Leukaemic phase (> 5.0 × 10^9/L)
- Cytopenias (WCC < 1.0 × 10^9/L and/or platelets < 100 × 10^9/L)

FLIPI

- Age > 60 years
- > 4 nodal sites
- LDH elevated
- Hb < 120 g/L
- Stage III/IV